These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 24697167)
1. Poly (ε-caprolactone) nanocapsules for oral delivery of raloxifene: process optimization by hybrid design approach, in vitro and in vivo evaluation. Aditya N; Ravi PR; Avula US; Vats R J Microencapsul; 2014; 31(5):508-18. PubMed ID: 24697167 [TBL] [Abstract][Full Text] [Related]
2. Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo evaluation and uptake mechanism. Ravi PR; Aditya N; Kathuria H; Malekar S; Vats R Eur J Pharm Biopharm; 2014 May; 87(1):114-24. PubMed ID: 24378615 [TBL] [Abstract][Full Text] [Related]
3. Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis. Saini D; Fazil M; Ali MM; Baboota S; Ali J Drug Deliv; 2015; 22(6):823-36. PubMed ID: 24725026 [TBL] [Abstract][Full Text] [Related]
4. Bioadhesive polymer/lipid hybrid nanoparticles as oral delivery system of raloxifene with enhancive intestinal retention and bioavailability. Du X; Gao N; Song X Drug Deliv; 2021 Dec; 28(1):252-260. PubMed ID: 33501870 [TBL] [Abstract][Full Text] [Related]
5. In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance. Ahmed OA; Badr-Eldin SM Int J Nanomedicine; 2018; 13():6325-6335. PubMed ID: 30349253 [TBL] [Abstract][Full Text] [Related]
6. Preparation and evaluation of raloxifene-loaded solid dispersion nanoparticle by spray-drying technique without an organic solvent. Tran TH; Poudel BK; Marasini N; Chi SC; Choi HG; Yong CS; Kim JO Int J Pharm; 2013 Feb; 443(1-2):50-7. PubMed ID: 23318367 [TBL] [Abstract][Full Text] [Related]
7. Enhanced oral bioavailability of the antiretroviral efavirenz encapsulated in poly(epsilon-caprolactone) nanoparticles by a spray-drying method. Tshweu L; Katata L; Kalombo L; Chiappetta DA; Hocht C; Sosnik A; Swai H Nanomedicine (Lond); 2014; 9(12):1821-33. PubMed ID: 24364871 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin. Wempe MF; Wacher VJ; Ruble KM; Ramsey MG; Edgar KJ; Buchanan NL; Buchanan CM Int J Pharm; 2008 Jan; 346(1-2):25-37. PubMed ID: 17644287 [TBL] [Abstract][Full Text] [Related]
9. Raloxifene-loaded SLNs with enhanced biopharmaceutical potential: QbD-steered development, in vitro evaluation, in vivo pharmacokinetics, and IVIVC. Jain A; Sharma T; Kumar R; Katare OP; Singh B Drug Deliv Transl Res; 2022 May; 12(5):1136-1160. PubMed ID: 33966178 [TBL] [Abstract][Full Text] [Related]
10. QbD-based optimization of raloxifene-loaded cubosomal formulation for transdemal delivery: ex vivo permeability and in vivo pharmacokinetic studies. Gupta T; Kenjale P; Pokharkar V Drug Deliv Transl Res; 2022 Dec; 12(12):2979-2992. PubMed ID: 35462597 [TBL] [Abstract][Full Text] [Related]
11. Self-Assembling Raloxifene Loaded Mixed Micelles: Formulation Optimization, In Vitro Cytotoxicity and In Vivo Pharmacokinetics. Kanade R; Boche M; Pokharkar V AAPS PharmSciTech; 2018 Apr; 19(3):1105-1115. PubMed ID: 29181706 [TBL] [Abstract][Full Text] [Related]
12. Enhanced bioavailability of raloxifene hydrochloride via dry suspensions prepared from drug/HP-β-cyclodextrin inclusion complexes. Lu R; Liu S; Wang Q; Li X Pharmazie; 2015 Dec; 70(12):791-7. PubMed ID: 26817276 [TBL] [Abstract][Full Text] [Related]
13. Proliposome powders for enhanced intestinal absorption and bioavailability of raloxifene hydrochloride: effect of surface charge. Velpula A; Jukanti R; Janga KY; Sunkavalli S; Bandari S; Kandadi P; Veerareddy PR Drug Dev Ind Pharm; 2013 Dec; 39(12):1895-906. PubMed ID: 22458264 [TBL] [Abstract][Full Text] [Related]
14. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736 [TBL] [Abstract][Full Text] [Related]
15. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study. O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Wolthers T; Davis SR Climacteric; 2003 Dec; 6(4):347-53. PubMed ID: 15006256 [TBL] [Abstract][Full Text] [Related]
16. [Effects of raloxifene combined with conjugated equine estrogen on prothrombotic state in ovariectomized rats]. Gao H; Xi S; Xu L Zhonghua Fu Chan Ke Za Zhi; 2013 Dec; 48(12):935-8. PubMed ID: 24495689 [TBL] [Abstract][Full Text] [Related]
17. Development of raloxifene-solid dispersion with improved oral bioavailability via spray-drying technique. Tran TH; Poudel BK; Marasini N; Woo JS; Choi HG; Yong CS; Kim JO Arch Pharm Res; 2013 Jan; 36(1):86-93. PubMed ID: 23325488 [TBL] [Abstract][Full Text] [Related]
18. Colon-targeted celecoxib-loaded Eudragit® S100-coated poly-ε-caprolactone microparticles: preparation, characterization and in vivo evaluation in rats. Ghorab DM; Amin MM; Khowessah OM; Tadros MI Drug Deliv; 2011; 18(7):523-35. PubMed ID: 21793779 [TBL] [Abstract][Full Text] [Related]
19. The effective encapsulation of a hydrophobic lipid-insoluble drug in solid lipid nanoparticles using a modified double emulsion solvent evaporation method. Nabi-Meibodi M; Vatanara A; Najafabadi AR; Rouini MR; Ramezani V; Gilani K; Etemadzadeh SM; Azadmanesh K Colloids Surf B Biointerfaces; 2013 Dec; 112():408-14. PubMed ID: 24036624 [TBL] [Abstract][Full Text] [Related]
20. Transdermal delivery of raloxifene HCl via ethosomal system: Formulation, advanced characterizations and pharmacokinetic evaluation. Mahmood S; Mandal UK; Chatterjee B Int J Pharm; 2018 May; 542(1-2):36-46. PubMed ID: 29501737 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]